Skip to content
Clinical Trials – home
Therapeutic area

Infections and infestations – page 34

  • 686 clinical trials
  • 263 recruiting
  • 279 conditions
  • 27 countries

Conditions in this area

279 conditions with trials, the busiest first

Clinical trials in Infections and infestations

686 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

686 clinical trials

COVID-19

Not yet recruiting

Study on Post-Acute COVID-19 Syndrome: Effects of Diet, Exercise, Metformin, and Sirolimus on Frailty and Immune Function in Affected Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Metformin
  • Sponsor:Azienda Ospedaliero Universitaria Di Modena

Study on the Effects of Plitidepsin for Adults with Long COVID Symptoms

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Dexchlorpheniramine
  • Sponsor:Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La Ciencia

Chronic hepatitis B

Not yet recruiting

Study of Tenofovir Alafenamide for Children and Teens with Chronic Hepatitis B

Registered drug
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Tenofovir Alafenamide
  • Sponsor:Gilead Sciences Inc.
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fosfomycin Trometamol
  • Sponsor:Centre Hospitalier Universitaire Rouen

Respiratory tract infection+3

Not yet recruiting

Study on the Safety of Mercaptamine with Standard Therapy for Hospitalized COVID-19 Pneumonia Patients Not Requiring High Oxygen Flows

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mercaptamine
  • Sponsor:National Institute For Infectious Diseases Lazzaro Spallanzani

Study of aneratrigine mesilate (iN1011-N17-02) to find the best dose for treating pain in adults with post-herpetic neuralgia

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Paracetamol
  • Sponsor:iN Therapeutics Co. Ltd.

Study on the Safety and Immune Response of RSVPreF3 OA Vaccine with PCV20 in Adults Aged 60 and Older with RSV Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Pneumococcal Polysaccharide Serotype 1 Conjugated To Crm197 Adsorbed On Aluminium Phosphate
  • Sponsor:GlaxoSmithKline Biologicals

Escherichia infection

Not recruiting

Study on the Safety and Immune Response of JNJ-78901563 and High-dose Influenza Vaccine in Preventing E. coli Infections in Adults Aged 65 and Older

Registered drug
Countries:BelgiumBelgium
  • Participants:65+ years · Healthy volunteers
  • Substances:ECOO15
  • Sponsor:Janssen Vaccines & Prevention B.V.

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Lyme disease

Not recruiting

Study on the Effectiveness and Safety of the VLA15 Vaccine for Preventing Lyme Disease in Healthy Individuals Aged 5 and Older

Registered drug
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Substances:Sodium chloride solution 0.9%
  • Sponsor:Pfizer Inc.

Influenza

Not recruiting

Study on the Effectiveness of an MF59-Adjuvanted Influenza Vaccine Compared to a Non-Adjuvanted Vaccine in Adults Aged 65 and Older

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years · Healthy volunteers
  • Substances:A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)
  • Sponsor:Seqirus UK Limited

Study on the Effects and Safety of Ginkgo Biloba Extract in Patients with Cognitive Impairment After COVID-19

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:REFINED AND QUANTIFIED DRY EXTRACT OF GINKGO BILOBA LEAVES (35-67:1) QUANTIFIED TO 22.0 TO 27.0 % OF FLAVONOIDS EXPRESSED AS FLAVONE GLYCOSIDES, 2.8 TO 3.4 % OF GINKGOLIDES A, B AND C, AND 2.6 TO 3.2 % OF BILOBALIDE. EXTRACTION SOLVENT: ACETONE 60% (M/M)
  • Sponsor:Dr. Willmar Schwabe GmbH & Co. KG

Substances studied in this area

The therapies tested most often in Infections and infestations trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.